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Background: Elevated glucose concentrations lead to increased insulin secretion and suppression of glucagon
secretion. In fact, insulin is a physiological inhibitor of glucagon secretion. Type 2 diabetes mellitus (T2DM)
patients have defects in insulin secretion. In addition to this, lack of suppression of glucagon secretion under
elevated glucose concentrations is also observed in T2DM patients. We have earlier shown that GPR40 activation
by CNX-011-67 stimulates glucose stimulated insulin secretion (GSIS). Here we extended our studies to examine
the impact of GPR40 activation by CNX-011-67 on glucagon secretion from intact islets under both normal and
glucolipotoxic conditions.
Findings: Glucagon secretion from intact rat islets was suppressed under elevated glucose concentration.
Activation of GPR40 by CNX-011-67 further suppressed glucagon secretion. Culturing islets under chronic glucolipotoxic
(GL) conditions, we have observed increased high glucose mediated glucagon secretion and content which were
reduced with GPR40 activation by CNX-011-67. Interestingly, expression of pre-proglucagon gene (GCG) remained
unchanged under glucolipotoxicity in the presence or absence of GPR40 activation.
Conclusion: Activation of GPR40 by CNX-011-67 can reduce glucagon secretion from pancreatic islets.
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Insulin and glucagon have opposing effects on blood glu-
cose level and hence a rigorous control on their secretion
is necessary for maintaining normoglycemia during both
fasting and post-prandial states. In T2DM patients, im-
paired beta cell insulin secretion and impaired suppression
of glucagon secretion from alpha cells lead to hypergluca-
gonemia mediated hyperglycemia [1,2]. We have reported
previously the development of CNX-011-67, a novel
GPR40 agonist, which showed significant impact on beta
cell health and insulin secretion [3]. Interestingly, Wang
et al. [4] reported that GPR40 activation by free fatty acids
could increase glucagon secretion in isolated pancreatic
alpha-cells [4]. However, we did not observe any change in
blood glucose levels in normal Wistar rats under fasting* Correspondence: m.r.jagannath@connexios.com
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unless otherwise stated.conditions by CNX-011-67 administration (unpublished
data). Given that GPR40 can increase insulin secretion
which is a physiological inhibitor of glucagon secretion;
we presumed that its impact on intact islets could be dif-
ferent from what seen in isolated alpha cells. Since ele-
vated glucose and insulin are known to suppress glucagon
secretion [5], we hypothesized that activation of GPR40 by
CNX-011-67 might also inhibit glucagon secretion in in-
tact islets. To prove our hypothesis, we studied the impact
of CNX-011-67 treatment on glucagon secretion in intact
islets under both normal and glucolipotoxic condition.Acute treatment of CNX-011-67 reduces glucagon
secretion
Isolated rat islets exposed to high glucose concentration
(11 mM) showed reduced glucagon secretion when com-
pared to islets treated with low glucose (0.5 mM) (20.5 ±
0.3 vs. 26.9 ± 0.9 pg/islet, P < 0.001; Figure 1A). In presenceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Activation of GPR40 by CNX-011-67 treatment reduces glucagon secretion. (A) Glucagon secretion was reduced under high
glucose condition and was further reduced by CNX-011-67 treatment. After culturing islets under vehicle control (VC) or chronic glucolipotoxic
(GL) conditions in presence or absence of CNX-011-67, islets were treated with high glucose concentration for 2 h and amount of secreted glucagon
(B), islet glucagon content (C) and glucagon secretion as % of content (D) were determined. After chronic culture, islets were used for gene expression
analysis and mRNA levels of glucagon (GCG) (E) and GPR40 (F) were quantified. Data are represented as mean ± SEM from four replicates and statistical
analyses were performed by ANOVA with Newman-Keuls post test (*P < 0.05, **P < 0.01 and ***P < 0.001).
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glucagon secretion (12.0 ± 1.1 vs. 20.5 ± 0.3 pg/islet, P <
0.001; Figure 1A). We earlier reported that CNX-011-67
treated islets showed enhanced insulin secretion in re-
sponse to increasing glucose concentration [6]. Hence it is
plausible that the enhanced insulin secretion by CNX-
011-67 might have reduced glucagon secretion in isolated
rat islets.
Impact of CNX-011-67 treatment on glucagon secretion
under chronic glucolipotoxic conditions
Intact rat islets were cultured under chronic glucolipotoxic
(GL) conditions for 72 h to mimic T2DM pathology [7]followed by an acute exposure (2 h) to high glucose con-
centration. Using the same assay conditions, we have earlier
shown that acute (2 h) high glucose induced insulin secre-
tion was reduced under GL conditions and was restored by
CNX-011-67 [3]. Exposure of islets to 11 mM glucose post
72 h treatment of GL condition elicited a higher glucagon
secretion than that observed in control islets (32.9 ± 2.3 vs.
22.2 ± 2.1 pg/islet, P < 0.001, Figure 1B). However, chronic
treatment with CNX-011-67 under GL conditions signifi-
cantly reduced glucagon secretion (21.7 ± 1 vs. 32.9 ±
2.3 pg/islet under GL, P < 0.01; Figure 1B). Hence, CNX-
011-67 reduced glucagon secretion under chronic GL
conditions.
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An increase in glucagon content was observed in islets cul-
tured under GL conditions (219.6 ± 8.1 vs. 122.7 ± 16.7 pg/
islet under VC, P < 0.001; Figure 1C). Chronic activation of
GPR40 by CNX-011-67 treatment under GL conditions re-
sulted in a partial but significant reduction in glucagon con-
tent (174.4 ± 16.1 vs. 219.6 ± 8.1 pg/islet under GL, P < 0.05;
Figure 1C). We earlier reported that under similar culture
conditions CNX-011-67 increased insulin content [3].
When glucagon secretion was normalized to the islet
glucagon content, we observed a significant reduction in
glucagon secretion as % of glucagon content, only upon
treatment with CNX-011-67 (11.1 ± 1.1 vs. 16.8 ± 1.1% of
content, P < 0.01; Figure 1D).
Glucolipotoxic conditions or CNX-011-67 treatment
showed no impact on pre-proglucagon gene expression
Since glucagon content and secretion were reduced by
CNX-011-67 treatment, we examined the impact on
pre-proglucagon (GCG) gene expression. We did not
observe any change in the expression of GCG in rat is-
lets under GL conditions or by CNX-011-67 treatment
(Figure 1E). Similar data were obtained from alpha-TC1,
a pancreatic alpha-cell line (data not shown). In contrast
to this unchanged GCG gene transcription by CNX-011-
67 treatment, we previously reported that CNX-011-67
treatment reversed the reduction in insulin gene tran-
scription caused by GL conditions [3].
GPR40 gene expression under GL conditions or
CNX-011-67 treatment
Islets cultured under GL conditions showed reduced
GPR40/FFAR1 expression (0.51 ± 0.11 fold of VC, P <
0.05, Figure 1F). Treatment with CNX-011-67 could mar-
ginally increased its expression (0.69 ± 0.18 vs. 0.51 ± 0.11
fold under GL, P > 0.05, Figure 1F). These data show that
CNX-011-67, which acts via activation of GPR40, has no
significant impact on its expression.
Taken together, chronic GPR40 activation by CNX-
011-67 treatment can reduce glucagon secretion and
content without any change in GCG expression. How-
ever, a previous study with a GPR40 agonist failed to
demonstrate any reduction in glucagon secretion. In that
study even GLP1, a known inhibitor of glucagon secre-
tion, failed to reduce glucagon secretion [8]. In order to
find out whether GPR40 mediated impacts were primar-
ily due to its action in alpha or beta cells, we measured
its expression in both cell types by comparative gene ex-
pression analysis. We observed that GPR40 expression
in an alpha cell line (alpha-TC1) was only 1.7% of that
observed in a beta cell line (NIT1) (data not shown).
These data are consistent with earlier finding [9] show-
ing almost exclusive expression of GPR40 in beta cellsand no expression in alpha cells. Interestingly, a similar
pattern for GLP1 receptor expression in alpha and beta
cells and its ability to increase insulin secretion and de-
crease glucagon secretion has been reported [10]. More-
over, during insulin granules exocytosis, ATP is also
released from beta-cells which can inhibit glucagon se-
cretion [11]. We have earlier shown that ATP levels are
increased in islets after GPR40 activation by CNX-011-
67 [6]. Hence suppressed glucagon secretion by GPR40
activation is mediated by the beta-cells secretory prod-
ucts but not by suppressing GCG expression. Hence, it
appears that primary site of action for GPR40 is beta
cells and its impacts on glucagon secretion are due to
increased insulin granules exocytosis. Based on the very
less expression of GPR40 in alpha cells and nature of
control of insulin on glucagon secretion, we consider
that CNX-011-67 mediated increase in insulin secretion
is a possible mechanism to reduce glucagon secretion
from intact islets. However, future studies are required
for a definitive answer.
Taken together, our data provide evidences that GPR40
activation can suppress glucagon secretion under patho-
logically relevant condition thus providing potential bene-
fit in reducing hyperglycemia.
Methods
Rat islet isolation, culture, treatment and gene expression
analysis
Rat islets were isolated and were cultured either as con-
trol (vehicle control, VC) or under GL conditions (con-
taining 16.7 mM glucose and 500 μM palmitate) for
72 h as described [7], in presence or absence of CNX-
011-67 (0.3 μM). Gene expression studies were carried
out as described [7]. Briefly, after 72 h of culture, islets
were harvested in Tri-reagent (Invitrogen) and total
RNA was isolated followed by first strand cDNA synthe-
sis using reverse transcriptase and random hexamer
(ABI, USA). Gene expression of target genes was mea-
sured using SYBR Green based PCR Master Mix (Euro-
genetic, Belgium) and beta-actin was used as an internal
control.
Estimation of glucagons secretion and content
For estimation of glucagon secretion after acute expos-
ure of CNX-011-67, rat islets were pretreated under low
glucose condition (0.5 mM) in presence or absence of
CNX-011-67 (0.1 μM) for 1 h. These islets were then in-
cubated under low (0.5 mM) or high glucose (11 mM)
for 2 h again in presence or absence of CNX-011-67.
Amount of glucagon secreted in supernatant was then
measured using glucagon ELISA kit (RnD Systems) as
per manufacturer’s protocol.
For estimation of secreted and cellular glucagon after
chronic treatment, rat islets were cultured under VC or
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72 h. Islets were washed and pretreated under low glucose
condition followed by incubation under high glucose for
2 h. The culture conditions were kept similar to our earlier
study where we measured insulin secretion [3]. The super-
natant was collected for estimating secreted glucagon and
the islets were lysed for estimating cellular glucagon using
ELISA kit (RnD Systems) and were represented as pg/islet.
Statistical analyses
Data from four biological replicates are presented as mean
with standard error of mean. For statistical analyses,
ANOVA with Newman-Keuls post test was performed
and P-values were calculated using GraphPad Prism. Stat-
istical significance is represented as *P < 0.05, **P < 0.01
and ***P < 0.001.
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